인쇄하기
취소

Celltrion’s ‘Truxima’ reaches 30% market share in Europe only in 3 months of launch

Published: 2017-08-03 09:58:49
Updated: 2017-08-03 09:58:49

‘Truxima,’ an antibody biosimilar launched by Celltrion Healthcare for the 2nd time in Europe, seems to rapidly grow in the European market.

Celltrion Healthcare announced on the 1st that ‘Truxima,’ an antibody biosimilar developed by Celltrion for the treatment of blood cancer, exceeded a 30% market share in some of the European countries, such as the U.K. and Netherlands, only in 3 months of...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.